Rhinomed today announces a fully underwritten non-renounceable rights issue of fully paid ordinary shares, to raise approximately A$3.54 million. The funds raised will be used to drive growth in Rhinomed’s major markets; support the Company’s leading products, including the Mute range of products (Nasal Dilator, Mouth Tape, Turbine Nasal Dilator) and the Rhinoswab range of … Read more
The world’s most child-friendly respiratory swab was launched in Europe today at Medica 2022 in Dusseldorf, Germany. Rhinoswab Junior is the first nasal swab developed specifically for children. Its unique design addresses one of the pandemics’ major challenges − testing reluctance − created by the fear, anxiety and discomfort associated with traditional combined throat and nose swabs. Rhinoswab Junior is … Read more
A new study suggests the traditional swab suffers from strong reluctance for use for children and a new Melbourne-designed Rhinoswab Junior is the preferred method of sample collection. The reluctance to test children for COVID-19 is due to the fear, anxiety and discomfort associated with the traditional combined throat and nose swabs. The “Less invasive … Read more
Rhinomed is pleased to advise of the forthcoming publication of a further study and data by researchers from the Murdoch Children’s Research Institute and the Royal Children’s Hospital (RCH) Melbourne confirming the efficacy and comfort of the world’s first nasal swab designed specifically for children – the Rhinoswab Junior. The study “Less invasive SARS-CoV-2 testing for children: … Read more
Rhinomed Limited is pleased to report that it has finalised an exclusive supply agreement with SureScreen Australia to supply Rhinoswabs and Rhinoswab Juniors for inclusion in SureScreen’s class-leading range of lateral flow point of care test kits in the Australian, New Zealand, Singapore and South Pacific markets. The first product to market will be the … Read more
Rhinomed has received an initial purchase order for one million Rhinoswabs from the Victorian Department of Health (DH) to support Victoria’s testing capability. This follows the recent NSW Health Pathology order of one million Rhinoswabs as announced on 11 August. Rhinomed’s Rhinoswab technology improves the sample collection process. As previously disclosed the Rhinoswab is substantially … Read more
Rhinomed has created the world’s first nasal swab designed specifically for children — The Rhinoswab Junior™ Ethics approval has been received for a clinical trial to commence with the Murdoch Children’s Research Institute (MCRI) at The Royal Children’s Hospital in Melbourne Trial seeks to further validate the child-friendly Rhinoswab Junior™ as a safe and effective alternative … Read more
Rhinomed has received purchase orders and begun supplying NSW Health Pathology with an initial one million Rhinoswabs as part of their program to support testing capability. The company has commenced deliveries with these initial orders being fulfilled over coming weeks. Rhinomed is now scaling up its manufacturing facilities to respond to growing domestic and international … Read more
Rhinomed is pleased to announce it has been advised by Medical Device Safety Service GmbH (MDSS) that an Authorized Representative’s Mandate according to the EU Regulation 2017/745 (MDR) is in place. As a result, Rhinomed has been issued a CE Certificate No.: 431330 for the new Rhinoswab. The successful registration and conformity with the relevant … Read more
Rhinomed is pleased to announce the appointment of Associate Professor John McBain AO as a Non Executive Director of the Company, effective immediately. Assoc. Prof. McBain is the former Head of Reproductive Services at The Royal Women’s Hospital in Melbourne, Australia. He is also the former President of the Fertility Society of Australia, and was … Read more
Rhinomed is pleased to report an important update on its Rhinoswab™ clinical program. In December 2020 the company established that the Rhinoswab was comparable to existing standard of care nasal swabs in detecting the SARS-CoV-2 virus in RT-PCR testing. This study was undertaken at the VIDRL (Peter Doherty Institute). Since December the company has further … Read more
Rhinomed is pleased to announce that the Australian Taxation Office has of today’s date refunded the R&D tax incentive amount in respect of the FY20 income tax year. The Company had previously lodged an application with AusIndustry which was approved. The Company then submitted its FY20 tax return, detailing the R&D tax incentive refund amount. … Read more
